Citations

Showing 10 of 108094 citations.

When is enteral nutrition indicated?
Bechtold, Matthew L. , Escuro, Arlene A. , Grenda, Brandee, Johnston, Theresa, Kozeniecki, Michelle , Limketkai, Berkeley N. , Nelson, Krystie K., Powers, Jan , Ronan, Andrea, Schober, Nathan, Strang, Brian J., Swartz, Cristina, Turner, Justine , Tweel, Lauren , Walker, Renee, Epp, Lisa , Escuro, Arlene , Kozeniecki, Michelle , Limketkai, Berkeley N , Malone, Ainsley , Brown, Patricia M., Johnston, Theresa, Malone, Ainsley

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | July 15, 2022 | Volume: 46 | Issue: 7 | Pages: 1470-1496

10.1002/jpen.2364 | PMID 35838308 Get It

AbstractEnteral nutrition (EN) is a vital component of nutrition around the world. EN allows for delivery of nutrients to those who cannot maintain adequate nutrition by oral intake alone. Common questions regarding EN are when to initiate and in what scenarios it is safe. The answers to these questions are often complex and require an evidence‐based approach. The Board of Directors of the American Society for Parenteral and Enteral Nutrition (ASPEN) established an Enteral Nutrition Committtee to address the important questions surrounding the indications for EN. Consensus recommendations were established based on eight extremely clinically relevant questions regarding EN indications as deemed by the Enteral Nutrition Committee. These consensus recommendations may act as a guide for clinicians and stakeholders on difficult questions pertaining to indications for EN. This paper was approved by the ASPEN Board of Directors.
Influence of endurance sports on atrial fibrillation ablation outcomes
Liu, Michael B. , Lee, Justin Z. , Klooster, Lindsay, Petty, Skye A. Buckner, Scott, Luis R. , Buckner Petty, Skye A, Liu, Michael

Mayo Clinic

Journal of Arrhythmia | July 15, 2022 | Volume: 38 | Issue: 5 | Pages: 694-709

10.1002/joa3.12746 | PMID 36237855 Get It

AbstractObjectivesWe aimed to investigate the outcomes of pulmonary vein isolation in athletes.MethodsWe retrospectively identified endurance athletes who underwent catheter ablation at our institution (2004–2018). Endurance athletes were defined as participating in competitive athletics for at least 1500 lifetime hours in sports at the IB or IIA Bethesda classification or higher. Primary endpoints were freedom from atrial arrhythmias at 12, 24, and 36 months after the procedure. Secondary endpoints were defined as qualitative improvement in symptoms allowing athletes to return to their previous level of activity. Athletes were compared with a control group of nonathletes in a 3‐to‐1 matched analysis by age and sex.ResultsA total of 39 endurance athletes who underwent catheter ablation were identified during the study period. At 12 months, there was no difference in treatment outcomes for athletes versus nonathletes (relative risk [RR], 1.06; 95% CI, 0.92–1.22; p = .40). Freedom from atrial arrhythmias was 35% less likely in athletes than nonathletes at 24 months (RR, 0.65; 95% CI, 0.50–0.83; p < .001) and 42% less likely at 36 months (RR, 0.58; 95% CI, 0.41–0.79; p < .001). Overall, 77% of the athletes were able to return to their previous level of activity following catheter ablation.ConclusionEndurance athletes with atrial fibrillation appear to have higher rates of atrial arrhythmia recurrence than nonathletes after catheter ablation, with higher rates of atypical flutter. The majority of athletes were able to return to their previous level of activity after ablation.
Considerations for determining the efficacy of new antiseizure medications in children age 1 month to younger than 2 years
French, Jacqueline A. , Cleary, Elena, Dlugos, Dennis , Farfel, Gail, Farrell, Kathleen , Grzeskowiak, Caitlin L. , Gurrell, Rachel , Harden, Cynthia L., Stalvey, Tracy, Tsai, Julia , Blum, David , Fountain, Nathan B. , Grzeskowiak, Caitlin L , Wirrell, Elaine C , Fountain, Nathan , French, Jacqueline , Gidal, Barry E. , Wirrell, Elaine

Mayo Clinic

Epilepsia | July 15, 2022 | Volume: 63 | Issue: 10 | Pages: 2664-2670

10.1111/epi.17366 | PMID 35835554 Get It

AbstractObjectivesDrug treatment for children with epilepsy should, ideally, be governed by evidence from adequate and well‐controlled clinical studies. However, these studies are difficult to conduct, and so direct evidence supporting the informed use of specific drugs is often lacking. The Research Roundtable for Epilepsy (RRE) met in 2020 to align on an approach to therapy development for focal seizures in children age 1 month <2 years of age.MethodsThe RRE reviewed the regulatory landscape, epidemiology, seizure semiology, antiseizure medicine pharmacology, and safety issues applicable to this population.ResultsAfter reviewing evidence, the conclusion was that pediatric efficacy trials would be impracticable to conduct but a waiver of the regulatory requirement to conduct any study would lead to an absence of information to guide dosing in a critical population. Review of available data and discussion of RRE attendees led to the conclusion that the requirements for extrapolation of efficacy from older children down to infants from age 1 month to <2 years old appeared to be met. After the RRE, the US Food and Drug Administration (FDA) approved brivaracetam for use in children with focal epilepsy above the age of 1 month in August 2021 and lacosamide in October 2021, both based on the principle of extrapolation from data in older children.SignificanceThese recommendations should result in more rapid accessibility of antiseizure medications for infants.
Association between Functional Parameters of Coagulation and Conventional Coagulation Tests in the Setting of Fluid Resuscitation with Balanced Crystalloid or Gelatine: A Secondary Analysis of an In Vivo Prospective Randomized Crossover Study
Wiórek, Agnieszka , Mazur, Piotr , Niemiec, Bożena, Krzych, Łukasz J. , Mazur, Piotr K

Mayo Clinic

Journal of Clinical Medicine | July 15, 2022 | Volume: 11 | Issue: 14 | Pages: 4065

10.3390/jcm11144065 | PMID 35887829 Get It

Functional point-of-care tests (POCTs) have evolved into useful tools for diagnosing disorders of blood coagulation and fibrinolysis. We aimed to describe the in vivo association between standard and functional parameters of coagulation and fibrinolysis in the setting of acute hemodilution induced by an infusion of balanced crystalloid or synthetic gelatine solutions. This prospective randomized crossover in vivo study included healthy male volunteers aged 18–30 years. Enrolled participants were randomly assigned to receive either the Optilyte® or Geloplasma® infusion. Laboratory analysis included conventional coagulation parameters and rotational thromboelastometry (ROTEM) assays. A total of 25 healthy Caucasian males were included. ROTEM viscoelastic assays presented moderate to strong correlations with conventional coagulation tests, regardless of the fluid type utilized. Irrespectively of the extent of hemodilution, significant correlations remained unaffected. The strongest associations were found between the ROTEM clot formation and clot strength and the fibrinogen concentration and platelet count, and between the ROTEM clotting time and the APTT and PT. This in vivo experimental study in healthy male volunteers demonstrated that ROTEM may be used as a credible alternative to standard laboratory tests to assess blood coagulation and fibrinolysis in the setting of fluid resuscitation with both crystalloid and colloid solutions. The study was registered online in the ClinicalTrials.gov database (NCT05148650).
Histopathology of Hidradenitis Suppurativa: A Systematic Review
Smith, Shane , Okoye, Ginette A. , Smith, Shane David Basil , Sokumbi, Olayemi

Mayo Clinic

Dermatopathology | July 15, 2022 | Volume: 9 | Issue: 3 | Pages: 251-257

10.3390/dermatopathology9030029 | PMID 35892482 Get It

Hidradenitis suppurativa (HS) is a chronic inflammatory scarring disease felt to be related to occlusion of the hair follicle unit in intertriginous areas. We perform a systematic review on HS histopathology to evaluate current knowledge and discuss future directions. PubMed and Scopus databases were searched for relevant articles published from January 1985 to January 2021 that discussed the pathology of HS. Additional articles were identified by hand-searching, which entailed manually scanning selected journals. A total of 355 citations were identified in the primary search within the main databases. Two hundred and seventy-nine articles were excluded after a review of titles, abstracts, and duplicates. Sixty-one studies did not meet the inclusion criteria or were found to be duplicates, resulting in a total of 15 articles for analysis. Three articles were hand-searched. This comprehensive systematic review of the histopathology of HS confirms a high prevalence of follicular occlusion, follicular hyperkeratosis, and hyperplasia of the follicular epithelium. These findings support the central role of follicular occlusion in the development and progression of HS while providing a potential path to directing therapeutics against follicular occlusion.
The Impact of Infused Autograft Absolute Numbers of Immune Effector Cells on Survival Post-Autologous Stem Cell Transplantation
Porrata, Luis F.

Mayo Clinic

Cells | July 15, 2022 | Volume: 11 | Issue: 14 | Pages: 2197

10.3390/cells11142197 | PMID 35883639 Get It

Autologous stem cell transplantation treatment has been viewed as a therapeutic modality to enable the infusion of higher doses of chemotherapy to eradicate tumor cells. Nevertheless, recent reports have shown that, in addition to stem cells, infusion of autograft immune effector cells produces an autologous graft-versus-tumor effect, similar to the graft-versus-tumor effect observed in allogeneic-stem cell transplantation, but without the clinical complications of graft-versus-host disease. In this review, I assess the impact on clinical outcomes following infusions of autograft-antigen presenting cells, autograft innate and adaptive immune effector cells, and autograft immunosuppressive cells during autologous stem cell transplantation. This article is intended to provide a platform to change the current paradigmatic view of autologous stem cell transplantation, from a high-dose chemotherapy-based treatment to an adoptive immunotherapeutic intervention.
Disparities in Metabolic Conditions and Cancer Characteristics among Hispanic Women with Breast Cancer: A Multi-Institutional Study
Jabbal, Iktej Singh , Dominguez, Barbara , Botrus, Gehan , Nahleh, Zeina , Jabbal, Iktej S , Dominguez, Barbara , Dwivedi, Alok , Bilani, Nadeem

Mayo Clinic

Cancers | July 15, 2022 | Volume: 14 | Issue: 14 | Pages: 3411

10.3390/cancers14143411 | PMID 35884473 Get It

While the associations of common metabolic conditions with ethnicity have been previously described, disparity among Hispanic individuals based on country of origin is understudied. This multi-institutional analysis explored the prevalence of metabolic conditions and their association with cancer subtypes among Mexican and non-Mexican Hispanics. After IRB approval, we conducted a cross-sectional study at two academic medical centers with a significant Hispanic patient population (Texas Tech University Health Sciences Center, El Paso, TX (TTUHSC-EP) and Cleveland Clinic Florida in Weston, FL (CCF)). A total of n = 1020 self-identified Hispanic patients with breast cancer consecutively diagnosed between 2005 and 2014 were selected from the two institutional databases. Comparisons between Mexican and Non-Mexican Hispanics revealed variations in tumor types and metabolic conditions. Mexican Hispanics were found to have a higher prevalence of diabetes mellitus (27.8% vs. 14.2%, p < 0.001), obesity (51.0% vs. 32.5%, p < 0.001), and ductal carcinoma type (86.6 vs. 73.4%, p < 0.001). On the other hand, hormone-receptor-positive breast cancer was more common in non-Mexicans, while Mexicans had more triple-negative breast cancer, especially in premenopausal women. In addition to highlighting these variations among Hispanic patients with breast cancer, this study supports a more focused approach to addressing obesity and other metabolic conditions prevalent in the Hispanic population with breast cancer. Moreover, Hispanic individuals with breast cancer are diverse and should not be lumped under one category without reference to their country of origin regarding the impact of race and ethnicity.
Body Mass Index Is Not a Stronger Predictor Than the Metabolic Syndrome for Future Asthma in Women
Linneberg, Allan , Agrawal, Anurag , Prakash, Y. S.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 15, 2022 | Volume: 189 | Issue: 2 | Pages: 231-232

10.1164/rccm.201307-1333le | PMID 24428655 Get It

Cryobiopsy, Endobronchial Ultrasound Staging of the Mediastinum, and Endobronchial Coils
Azadeh, Natalya , Clay, Ryan , Braus, Nicholas, Ramar, Kannan , Clay, Ryan D, Braus, Nicholas A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 14, 2022 | Volume: 195 | Issue: 3 | Pages: 394-396

10.1164/rccm.201609-1840rr | PMID 27911567 Get It

Comparing Outcomes and Cost Between Pancreas Transplant and Standard of Care in Patients With Type 1 Diabetes
Thao, Viengneesee , Spaulding, Aaron , Jarmi, Tambi , Borah, Bijan J. , Moriarty, James P. , Spaulding, Aaron C. , Spaulding, Aaron , Brennan, Emily

Mayo Clinic

Pancreas | July 14, 2022 | Volume: 51 | Issue: 5 | Pages: 483-489

10.1097/mpa.0000000000002053 | PMID 35835120 Get It

Objectives Pancreas transplant is the only treatment that establishes normal glucose levels for patients diagnosed with diabetes. We analyzed the outcome of pancreas transplant alone (PTA) versus standard of care in the United States from 2008 to 2018. We also developed an economic model to analyze the cost-effectiveness of pancreas transplant versus continuing standard of care. Methods We used the Scientific Registry of Transplant Recipients database and analyzed PTA recipient survival. Using those results, we developed a Markov model that followed a cohort of 40-year-old patients with type 1 diabetes over a 10-year time horizon. The primary outcomes were (i) the survival benefit of a pancreas transplant, (ii) quality-adjusted life-years (QALYs), and (iii) total costs. Results We found no difference in survival advantage of PTA compared with standard of care (hazard ratio, 1.09; 95% confidence interval, 0.56–2.14). However, pancreas transplant ($172,823, 6.87 QALY) was cost-saving compared with standard of care ($232,897, 6.04 QALY) for type 1 diabetes. Pancreas transplantation was cost-effective in 95% of 10,000 simulations in probabilistic sensitivity analysis, using a $100,000/QALY willingness-to-pay threshold. Conclusions Although there is no difference in survival for PTA compared with standard of care, PTA is a cost-saving therapy for type 1 diabetes.